Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 33 (1), 53-58

Curcumin Use in Ulcerative Colitis: Is It Ready for Prime Time? A Systematic Review and Meta-Analysis of Clinical Trials


Curcumin Use in Ulcerative Colitis: Is It Ready for Prime Time? A Systematic Review and Meta-Analysis of Clinical Trials

Saurabh Chandan et al. Ann Gastroenterol.


Background: Curcumin, an active ingredient of the Indian herb turmeric (Curcuma longa), has shown promising anti-inflammatory properties. Studies of its potential benefits in treating patients with ulcerative colitis (UC) are limited. We performed a systematic review and meta-analysis of human randomized placebo controlled trials to evaluate the efficacy of adjunctive therapy with curcumin in treating patients with UC.

Methods: We conducted a search of several databases (from January 2000 to September 2018). A random-effects model was used for analysis. We assessed heterogeneity between study-specific estimates using the Cochran Q statistical test, 95% prediction interval (PI) and I2 statistics. The outcomes assessed were the pooled odds of clinical response and remission as well as the endoscopic response.

Results: A total of 7 studies with 380 patients (curcumin n=188; placebo n=190) were included in the final analysis. The pooled odds ratio for clinical remission with curcumin use was 2.9 (95%CI 1.5-5.5, I2=45, P=0.002), clinical response was 2.6 (95%CI 1.5-4.5, I2=74%, P=0.001), and endoscopic response/remission was 2.3 (95%CI 1.2-4.6, I2=35.5%, P=0.01).

Conclusions: Based on our study, combined mesalamine and curcumin therapy was associated with roughly threefold better odds of a clinical response compared to placebo, with minimal side effects. This response was statistically significant, albeit with heterogeneity, probably due to the different severity scoring indices, curcumin dosages and routes of drug delivery used.

Keywords: Ulcerative colitis; curcumin; meta-analysis.

Conflict of interest statement

Conflict of Interest: None


Figure 1
Figure 1
Forest plot. Clinical remission CI, confidence interval
Figure 2
Figure 2
Forest plot. Clinical response CI, confidence interval
Figure 3
Figure 3
Forest plot. Endoscopic response CI, confidence interval

Similar articles

See all similar articles


    1. Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol. 1991;26:1247–1256. - PubMed
    1. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis:a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260–266. - PubMed
    1. Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA technical review on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156:769–808. - PMC - PubMed
    1. Panahi Y, Khalili N, Sahebi E, et al. Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus:a randomized double-blind placebo-controlled trial. Drug Res (Stuttg) 2018;68:403–409. - PubMed
    1. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease:a randomized controlled trial. J Cardiovasc Pharmacol. 2016;68:223–229. - PubMed